Literature DB >> 22143135

Chemotherapy: New FluCam combination therapy has familiar limitations.

Jennifer A Woyach, John C Byrd.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 22143135     DOI： 10.1038/nrclinonc.2011.191

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  8 in total

1.  The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia.

Authors:  L F Diehl; L H Karnell; H R Menck
Journal:  Cancer       Date:  1999-12-15       Impact factor: 6.860

2.  Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Authors:  Michael J Keating; Ian Flinn; Vinay Jain; Jacques-Louis Binet; Peter Hillmen; John Byrd; Maher Albitar; Lee Brettman; Pedro Santabarbara; Bret Wacker; Kanti R Rai
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

Review 3.  The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.

Authors:  Samantha M Jaglowski; Lapo Alinari; Rosa Lapalombella; Natarajan Muthusamy; John C Byrd
Journal:  Blood       Date:  2010-07-07       Impact factor: 22.113

4.  Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.

Authors:  Thomas Elter; Liana Gercheva-Kyuchukova; Halyna Pylylpenko; Tadesuz Robak; Branimir Jaksic; Grigoriy Rekhtman; Sławomira Kyrcz-Krzemień; Mykola Vatutin; Jingyang Wu; Cynthia Sirard; Michael Hallek; Andreas Engert
Journal:  Lancet Oncol       Date:  2011-10-10       Impact factor: 41.316

5.  Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.

Authors:  Stephan Stilgenbauer; Thorsten Zenz; Dirk Winkler; Andreas Bühler; Richard F Schlenk; Silja Groner; Raymonde Busch; Manfred Hensel; Ulrich Dührsen; Jürgen Finke; Peter Dreger; Ulrich Jäger; Eva Lengfelder; Karin Hohloch; Ulrike Söling; Rudolf Schlag; Michael Kneba; Michael Hallek; Hartmut Döhner
Journal:  J Clin Oncol       Date:  2009-07-13       Impact factor: 44.544

6.  Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.

Authors:  Peter Hillmen; Aleksander B Skotnicki; Tadeusz Robak; Branimir Jaksic; Anna Dmoszynska; Jingyang Wu; Cynthia Sirard; Jiri Mayer
Journal:  J Clin Oncol       Date:  2007-11-05       Impact factor: 44.544

7.  Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Authors:  Gerard Lozanski; Nyla A Heerema; Ian W Flinn; Lisa Smith; Jennifer Harbison; Jennifer Webb; Mollie Moran; Margaret Lucas; Thomas Lin; Marcy L Hackbarth; John H Proffitt; David Lucas; Michael R Grever; John C Byrd
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

Review 8.  Management of infectious complications in patients with chronic lymphocytic leukemia.

Authors:  Vicki A Morrison
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2007
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.